Role of microRNAs in the pathophysiology of atherosclerosis and their potential clinical use
Authors:
Jan Novák 1,2; Miroslav Souček 1
Authors‘ workplace:
II. interní klinika LF MU a FN U sv. Anny v Brně
1; Fyziologický ústav LF MU, Brno
2
Published in:
AtheroRev 2016; 1(3): 144-150
Category:
Reviews
Overview
Atherosclerosis and its clinical manifestations (such as myocardial infarction or stroke) still remain the leading cause of death in developed countries. In recent decades our knowledge about the origin of atherosclerosis has considerably advanced; key molecules and signalling cascades involved in this complex process have been described, which enabled the development of effective therapeutic procedures that can moderate the effects of atherosclerosis on an individual's health. The discovery of non-coding RNAs (ncRNA) which participate in the regulation of gene expression and are involved in almost all the processes in the body, has revealed yet another level of complexity, it offers a new insight into the regulation of individual processes and, not least, also new procedures utilizable in diagnostics or therapy for atherosclerosis. This overview presents essential information about the function of microRNA, one of the ncRNA groups, and further discusses their involvement in the pathogenesis of atherosclerosis. The last part of the text provides an overview of possible uses of circulating microRNAs in diagnosing atherosclerosis and uses the results of animal as well as pilot human studies to also demonstrate the therapeutic potential which is hidden in these small molecules.
Key words:
circulating microRNA – diagnosing atherosclerosis – ncRNA – therapy for atherosclerosis
Sources
1. Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Intern Med 2015; 278(5): 483–493. Dostupné z DOI: <http://dx.doi.org/10.1111/joim.12406>.
2. Feinberg MW, Moore KJ. MicroRNA Regulation of Atherosclerosis. Circ Res 2016; 118(4): 703–720. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.115.306300>.
3. Sun X, Sit A, Feinberg MW. Role of miR-181 family in regulating vascular inflammation and immunity. Trends Cardiovasc Med 2014; 24(3): 105–112. Dostupné z DOI: <http://dx.doi.org/10.1016/j.tcm.2013.09.002>.
4. Kumar S, Kim CW, Simmons RD et al. Role of flow-sensitive microRNAs in endothelial dysfunction and atherosclerosis: mechanosensitive athero-miRs. Arterioscler Thromb Vasc Biol 2014; 34(10): 2206–2216. Dostupné z DOI: <http://dx.doi.org/10.1161/ATVBAHA.114.303425>.
5. Davis-Dusenbery BN, Chan MC, Reno KE et al. down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. J Biol Chem 2011; 286(32): 28097–28110. Dostupné z DOI: <http://dx.doi.org/10.1074/jbc.M111.236950>.
6. Taft RJ, Pang KC, Mercer TR et al. Non-coding RNAs: regulators of disease. J Pathol 2010; 220(2): 126–139. Dostupné z DOI: <http://dx.doi.org/10.1002/path.2638>.
7. Mattick JS. Non-coding RNAs: the architects of eukaryotic complexity. EMBO Rep 2001; 2(11): 986–991.
8. Djebali S, Davis CA, Merkel A et al. Landscape of transcription in human cells. Nature 2012; 489(7414): 101–108. Dostupné z DOI: <http://dx.doi.org/10.1038/nature11233>.
9. Hombach S, Kretz M. Non-coding RNAs: Classification, Biology and Functioning. Adv Exp Med Biol 2016; 937: 3–17. Dostupné z DOI: <http://dx.doi.org/10.1007/978–3-319–42059–2_1>.
10. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281–297.
11. Novák J, Olejníčková V, Tkáčová N et al. Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis. Adv Exp Med Biol 2015; 887: 79–100. Dostupné z DOI: <http://dx.doi.org10.1007/978–3-319–22380–3_5>. Erratum in Adv Exp Med Biol 2015; 888: E1-E2.
12. Creemers EE, Tijsen AJ, Pinto YM. Circulating MicroRNAs Novel Biomarkers and Extracellular Communicators in Cardiovascular Disease? Circ Res 2012; 110(3): 483–495. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.111.247452>.
13. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 2012; 11(11): 860–872. Dostupné z DOI: <http://dx.doi.org/10.1038/nrd3864>.
14. Eberlé D, Hegarty B, Bossard P et al. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 2004; 86(11): 839–848.
15. Najafi-Shoushtari SH, Kristo F, Li Y et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010; 328(5985): 1566–1569. Dostupné z DOI: <http://dx.doi.org/10.1126/science.1189123>.
16. Allen RM, Marquart TJ, Albert CJ, et al. miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity. EMBO Mol Med 2012; 4(9): 882–895. Dostupné z DOI: <http://dx.doi.org/10.1002/emmm.201201228>.
17. Rayner KJ, Sheedy FJ, Esau CC et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011; 121(7): 2921–2931. Dostupné z DOI: <http://dx.doi.org/10.1172/JCI57275>.
18. Rayner KJ, Esau CC, Hussain FN et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011; 478(7369): 404–407. Dostupné z DOI: <http://dx.doi.org/10.1038/nature10486>.
19. Ouimet M, Ediriweera HN, Gundra UM et al. MicroRNA-33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis. J Clin Invest 2015; 125(12): 4334–4348. Dostupné z DOI: <http://dx.doi.org/10.1172/JCI81676>.
20. Shirasaki T, Honda M, Shimakami T et al. MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. J Virol 2013; 87(9): 5270–5286. Dostupné z DOI: <http://dx.doi.org/10.1128/JVI.03022–12>.
21. Vickers KC, Shoucri BM, Levin MG et al. MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatol Baltim Md 2013; 57(2): 533–542. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.25846>.
22. Vickers KC, Landstreet SR, Levin MG et al. MicroRNA-223 coordinates cholesterol homeostasis. Proc Natl Acad Sci U S A 2014; 111(40): 14518–14523. Dostupné z DOI: <http://dx.doi.org/10.1073/pnas.1215767111>.
23. Soh J, Iqbal J, Queiroz J et al. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med 2013; 19(7): 892–900. Dostupné z DOI: <http://dx.doi.org/10.1038/nm.3200>.
24. Goedeke L, Rotllan N, Canfrán-Duque A et al. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat Med 2015; 21(11): 1280–1289. Dostupné z DOI: <http://dx.doi.org/10.1038/nm.3949>.
25. Tabet F, Vickers KC, Cuesta Torres LF et al. HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat Commun 2014; 5: 3292. Dostupné z DOI: <http://dx.doi.org/10.1038/ncomms4292>.
26. Suárez Y, Wang C, Manes TD et al. Cutting edge: TNF-induced microRNAs regulate TNF-induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: feedback control of inflammation. J Immunol 2010; 184(1): 21–25. Dostupné z DOI: <http://dx.doi.org/10.4049/jimmunol.0902369>.
27. Jansen F, Yang X, Baumann K et al. Endothelial microparticles reduce ICAM-1 expression in a microRNA-222-dependent mechanism. J Cell Mol Med 2015; 19(9): 2202–2214. Dostupné z DOI: <http://dx.doi.org/10.1111/jcmm.12607>.
28. Harris TA, Yamakuchi M, Ferlito M et al. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A 2008; 105(5): 1516–1521. Dostupné z DOI: <http://dx.doi.org/10.1073/pnas.0707493105>.
29. Sun X, He S, Wara AKM et al. Systemic delivery of microRNA-181b inhibits nuclear factor-κB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice. Circ Res 2014; 114(1): 32–40. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.113.302089>.
30. Cheng HS, Sivachandran N, Lau A et al. MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol Med 2013; 5(7): 1017–1034. Dostupné z DOI: <http://dx.doi.org/10.1002/emmm.201202318>.
31. Zhou J, Li Y-S, Nguyen P et al. Regulation of vascular smooth muscle cell turnover by endothelial cell-secreted microRNA-126: role of shear stress. Circ Res 2013; 113(1): 40–51. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.113.280883>.
32. Hergenreider E, Heydt S, Tréguer K et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol 2012; 14(3): 249–256. Dostupné z DOI: <http://dx.doi.org/10.1038/ncb2441>.
33. Boettger T, Beetz N, Kostin S et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 2009; 119(9): 2634–2647. Dostupné z DOI: <http://dx.doi.org/10.1172/JCI38864>.
34. Lovren F, Pan Y, Quan A et al. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation 2012; 126(11 Suppl 1): S81–S90.
35. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18(10): 997–1006. Dostupné z DOI: <http://dx.doi.org/10.1038/cr.2008.282>.
36. Xin Y, Yang C, Han Z. Circulating miR-499 as a potential biomarker for acute myocardial infarction. Ann Transl Med 2016; 4(7): 135. Dostupné z DOI: <http://dx.doi.org/10.21037/atm.2016.03.40>.
37. Lee EJ, Baek M, Gusev Y et al. Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. RNA 2008; 14(1): 35–42.
38. Heggermont WA, Heymans S. MicroRNAs Are Involved in End-Organ Damage During Hypertension. Hypertension 2012; 60(5): 1088–1093. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.187104>.
39. Navickas R, Gal D, Laucevičius A et al. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovasc Res 2016; 111(4): 322–337. Dostupné z DOI: <http://dx.doi.org/10.1093/cvr/cvw174>.
40. Zhang J-Y, Gong Y-L, Li C-J et al. Circulating MiRNA biomarkers serve as a fingerprint for diabetic atherosclerosis. Am J Transl Res 2016; 8(6): 2650–2658.
41. Volný O, Kašičková L, Coufalová D et al. microRNAs in Cerebrovascular Disease. Adv Exp Med Biol 2015; 888: 155–195. Dostupné z DOI: <http://dx.doi.org/10.1007/978–3-319–22671–2_9>.
42. Janssen HLA, Reesink HW, Lawitz EJ et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368(18): 1685–1694. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa120902>.
43. Duell PB, Santos RD, Kirwan BA et al. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. J Clin Lipidol 2016; 10(4): 1011–1021. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacl.2016.04.013>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2016 Issue 3
Most read in this issue
- Arterin® – doplněk stravy v léčbě dyslipidemie: výsledky krátkodobého klinického sledování
- Atherogenic dyslipidemia – a new target in cardiovascular prevention
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
- Peripheral arterial disease (PAD) of lower extremity and dyslipidemia